The Chemours Company $CC Shares Sold by Allianz Asset Management GmbH

Allianz Asset Management GmbH lowered its position in shares of The Chemours Company (NYSE:CC) by 30.0% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 468,824 shares of the specialty chemicals company’s stock after selling 200,779 shares during the quarter. Allianz Asset Management GmbH owned about 0.31% of Chemours worth $5,368,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. Yousif Capital Management LLC lifted its holdings in shares of Chemours by 1.6% in the 2nd quarter. Yousif Capital Management LLC now owns 62,386 shares of the specialty chemicals company’s stock worth $714,000 after purchasing an additional 968 shares during the last quarter. CWM LLC lifted its holdings in shares of Chemours by 34.7% in the 2nd quarter. CWM LLC now owns 4,290 shares of the specialty chemicals company’s stock worth $49,000 after purchasing an additional 1,104 shares during the last quarter. Brown Advisory Inc. lifted its holdings in shares of Chemours by 6.0% in the 1st quarter. Brown Advisory Inc. now owns 20,874 shares of the specialty chemicals company’s stock worth $282,000 after purchasing an additional 1,174 shares during the last quarter. Inspire Investing LLC lifted its holdings in shares of Chemours by 5.7% in the 1st quarter. Inspire Investing LLC now owns 25,156 shares of the specialty chemicals company’s stock worth $340,000 after purchasing an additional 1,357 shares during the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Chemours by 170.7% in the 1st quarter. Farther Finance Advisors LLC now owns 2,290 shares of the specialty chemicals company’s stock worth $30,000 after purchasing an additional 1,444 shares during the last quarter. Institutional investors own 76.26% of the company’s stock.

Insider Transactions at Chemours

In other news, CEO Denise Dignam purchased 4,068 shares of the stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the completion of the purchase, the chief executive officer directly owned 191,546 shares of the company’s stock, valued at approximately $2,310,044.76. The trade was a 2.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.47% of the stock is owned by corporate insiders.

Chemours Trading Up 1.1%

Chemours stock opened at $13.51 on Thursday. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68. The business’s 50-day simple moving average is $15.33 and its 200-day simple moving average is $13.04. The firm has a market capitalization of $2.02 billion, a PE ratio of -4.82 and a beta of 1.65. The Chemours Company has a 52 week low of $9.13 and a 52 week high of $22.38.

Chemours (NYSE:CC) last posted its quarterly earnings data on Tuesday, August 5th. The specialty chemicals company reported $0.58 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.12. The business had revenue of $1.62 billion for the quarter, compared to analyst estimates of $1.57 billion. Chemours had a positive return on equity of 35.14% and a negative net margin of 7.19%.The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.38 earnings per share. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts forecast that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 15th were paid a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.6%. The ex-dividend date was Friday, August 15th. Chemours’s payout ratio is currently -12.50%.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Mizuho cut their price target on Chemours from $19.00 to $18.00 and set an “outperform” rating on the stock in a report on Thursday, October 16th. UBS Group increased their price target on Chemours from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, October 6th. Truist Financial increased their price target on Chemours from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 16th. Zacks Research lowered Chemours from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Chemours in a research note on Wednesday, October 8th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Chemours presently has an average rating of “Hold” and a consensus price target of $18.50.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.